Original Research

Published on 07 May 2024

Effects of plant protease inhibitors (Pep-3-EcTI, Pep-BbKI, and Pep-BrTI) versus corticosteroids on inflammation, remodeling, and oxidative stress in an asthma–COPD (ACO) model

in Respiratory Pharmacology

Juliana Morelli Lopes Gonçalves João
Jéssica Anastácia Silva Barbosa
Luana Laura Sales da Silva
Silvia Fukuzaki
Elaine Cristina de Campos
Leandro do Nascimento Camargo
Tabata Maruyama dos Santos
Suellen Karoline Moreira Bezerra
Francine Maria de Almeida
Beatriz Mangueira Saraiva-Romanholo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1282870

1,559 views
1 citation

Editorial

Published on 25 Apr 2024

Editorial: Pathogen targeting in chronic respiratory diseases: prevention, therapy and management

in Respiratory Pharmacology

Shakti D. Shukla
Kamal Dua
Ronan F. O’Toole

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1407616

663 views

Original Research

Published on 18 Apr 2024

Fentanyl activates opposing opioid and non-opioid receptor systems that control breathing

in Respiratory Pharmacology

Santhosh M. Baby
Walter J. May
Paulina M. Getsy
Gregory A. Coffee
Tej Nakashe
James N. Bates
Alan Levine
Stephen J. Lewis

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1381073

1,801 views
1 citation

Review

Published on 27 Mar 2024

Functional roles of circular RNAs in lung injury

in Respiratory Pharmacology

Fei-Fei Gao
Dian-Qing Chen
Yue-Tong Jiang
Cui-Fei Han
Bi-Yun Lin
Zhan Yang
Juan-Hua Quan
Ying-Huan Xiong
Xin-Tian Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1354806

1,454 views

Original Research

Published on 25 Mar 2024

Mechanisms of Bushenyiqi decoction in the treatment of asthma: an investigation based on network pharmacology with experimental validation

in Respiratory Pharmacology

Ziwen Qin
Yujuan Chen
Na Liu
Yonggang Wang
Lili Su
Bin Liang
Chuanjun Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1361379

11,195 views
1 citation

Original Research

Published on 18 Mar 2024

Long-term benefits of EPs® 7630 in patients with acute sinusitis: a real-world cohort study

in Respiratory Pharmacology

Matthias Tisch
Lubomír Roháč
Thorsten Reineke
Martin Burkart
Karel Kostev

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1358879

1,706 views
1 citation

Original Research

Published on 14 Mar 2024

CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

in Respiratory Pharmacology

Cataldo Martucci
Andrew Dennis Allen
Nadia Moretto
Valentina Bagnacani
Alessandro Fioni
Riccardo Patacchini
Maurizio Civelli
Gino Villetti
Fabrizio Facchinetti

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1343941

2,941 views
1 citation

Original Research

Published on 13 Mar 2024

Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats

in Respiratory Pharmacology

Nicole Reyne
Patricia Cmielewski
Alexandra McCarron
Ronan Smith
Elena Schneider-Futschik
Nina Eikelis
Piraveen Pirakalathanan
David Parsons
Martin Donnelley

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1362325

1,450 views
4 citations

Review

Published on 07 Mar 2024

The role of inflammation in silicosis

in Respiratory Pharmacology

Tong-Tong Liu
Hai-Fei Sun
Yan-Xing Han
Yun Zhan
Jian-Dong Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1362509

3,439 views
5 citations

Correction

Published on 07 Mar 2024

Corrigendum: Unravelling the therapeutic potential of botanicals against chronic obstructive pulmonary disease (COPD): molecular insights and future perspectives

in Respiratory Pharmacology

Sicon Mitra
Uttpal Anand
Mimosa Ghorai
Balachandar Vellingiri
Niraj Kumar Jha
Tapan Behl
Manoj Kumar
Radha
Mahipal S. Shekhawat
Jarosław Proćków

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1365790

792 views

Original Research

Published on 23 Feb 2024

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

in Respiratory Pharmacology

Menglin He
Taoran Yang
Jian Zhou
Rurong Wang
Xuehan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1310286

3,492 views
3 citations

Original Research

Published on 21 Feb 2024

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

in Respiratory Pharmacology

Aleksandr S. Chernov
Maksim V. Rodionov
Vitaly A. Kazakov
Karina A. Ivanova
Fedor A. Meshcheryakov
Anna A. Kudriaeva
Alexander G. Gabibov
Georgii B. Telegin
Alexey A. Belogurov

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1351655

2,191 views
2 citations

Original Research

Published on 13 Feb 2024

Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix

in Respiratory Pharmacology

Xuanyu Wu
Xiang Xiao
Hanyu Fang
Cuifang He
Hanyue Wang
Miao Wang
Peishu Lan
Fei Wang
Quanyu Du
Han Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1348708

3,698 views

Original Research

Published on 07 Feb 2024

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan

in Respiratory Pharmacology

Kuang-Ming Liao
Chung-Yu Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1309712

2,570 views
2 citations

Original Research

Published on 10 Jan 2024

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study

in Respiratory Pharmacology

Hélène Salvator
Elodie Lamy
Camille Roquencourt
Emmanuelle Bardin
Philippe Devillier
Stanislas Grassin-Delyle

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1339835

1,154 views

Review

Published on 08 Jan 2024

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

in Respiratory Pharmacology

Diya Garg
Loretta G. Que
Jennifer L. Ingram

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1315540

3,392 views
6 citations

Navigation group

Articles

Effects of plant protease inhibitors (Pep-3-EcTI, Pep-BbKI, and Pep-BrTI) versus corticosteroids on inflammation, remodeling, and oxidative stress in an asthma–COPD (ACO) model

Editorial: Pathogen targeting in chronic respiratory diseases: prevention, therapy and management

Fentanyl activates opposing opioid and non-opioid receptor systems that control breathing

Functional roles of circular RNAs in lung injury

Mechanisms of Bushenyiqi decoction in the treatment of asthma: an investigation based on network pharmacology with experimental validation

Long-term benefits of EPs® 7630 in patients with acute sinusitis: a real-world cohort study

CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats

The role of inflammation in silicosis

Corrigendum: Unravelling the therapeutic potential of botanicals against chronic obstructive pulmonary disease (COPD): molecular insights and future perspectives

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity